<DOC>
	<DOC>NCT01392469</DOC>
	<brief_summary>This study will investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to pulmonary arterial hypertension patients.</brief_summary>
	<brief_title>Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Pulmonary arterial hypertension (PAH) patients in WHO Diagnostic Group 1, with pulmonary vascular resistance &gt; 800 dyne•sec•cm5, On stable doses of bosentan and sildenafil Other diagnosis of PAH in WHO Diagnostic Group 1 such as congenital large or small unrepaired systemic to pulmonary shunts, portal hypertension,HIV infection, glycogen storage disease, Gaucher's disease, hereditary hemorrhagic teleangiectasia, hemoglobinopathies, myeloproliferative disorders, venoocclusive pulmonary disease Significant lung diseases not related to PAH Significant cardiovascular system disorders, hematological system disorders, liver insufficiency Significant diseases in other organ system. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>pulmonary vascular resistance</keyword>
	<keyword>imatinib</keyword>
	<keyword>bosentan</keyword>
	<keyword>sildenafil</keyword>
</DOC>